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The crystal structure of the molecular complex of eglin, a serine proteinase inhibitor from leeches, with sub- 
tilisin Carlsberg has been determined at 2.0 A resolution by the molecular replacement method. The com- 
plex has been relined by restrained-parameter least-squares. The present crystallographic R factor 
(=CI ]13,\-]1;1 I/ClF,I) is 0.183. Eglin is a member of the potato inhibitor 1 family, a group of serine protein- 
ase inhibitors lacking disultide bonds. Eglin shows strong structural homology to CL2, a related inhibitor 
from barley seeds. The structure of subtilisin Carlsberg in this complex is very similar to the known structure 
of subtilisin novo, despite changes of 84 out of 274 amino acids. 
Potato inhibitor 1 Serine proteinase Molecular replacement method Hirudo medicinalis Crystallography 
1. INTRODUCTION 
Amino-acid sequence homologies have estab- 
lished several families of serine proteinase in- 
hibitors [l]. Members of 6 of these families have 
now been studied by X-ray crystallographic 
methods. Eglin, a small protein from the leech 
Hirudo medicinalis, is a member of the potato in- 
hibitor 1 family [2,3]. Some of the proteins in this 
family lack the stabilizing disulfide bonds that are 
thought to contribute to the inhibitory effect of 
most other serine proteinase inhibitors. Thus, their 
3-dimensional structures are of interest in 
elucidating those features contributing to their in- 
hibitory properties. Eglin is a potent inhibitor of 
granulocytic elastase and cathepsin G [4] and may 
have important therapeutic medical applications. 
Here, we have used the genetically engineered 
product eglin-c rather than the naturally occurring 
protein from leeches. 
Subtilisin Carlsberg is a bacterial serine pro- 
teinase from Bacillus subtilis. It is highly 
homologous to subtilisins novo and BPN’, whose 
+ To whom reprint requests should be addressed 
crystal structures are known [5,6], and has similar 
catalytic properties. Eglin-c forms a strong com- 
plex with subtilisin [4]. 
The structure of chymotrypsin inhibitor 2 (CI-2) 
from barley seeds in complex with subtilisin novo 
has been determined and refined at 2.1 A resolu- 
tion to a current crystallographic R factor (R = 
Cl IF,1 - IF,1 I/CIF’I where F, and Fc are the 
observed and calculated structure factors, respec- 
tively) of 0.193 (McPhalen and James, unpub- 
lished). CI-2 is another member of the potato in- 
hibitor 1 family and is homologous to eglin [3]. 
We present here the 3-dimensional X-ray 
crystallographic structure of the eglin-c : subtilisin 
Carlsberg complex, refined to an R factor of 0.183 
for data in the resolution range 6.0-2.0 A, and 
compare the structure with that of the CI-2: sub- 
tilisin novo complex. 
2. MATERIALS AND METHODS 
2.1. Crystallization 
Purified lyophilized eglin-c (batch no.84, 25-4) 
was obtained from Ciba-Geigy, Switzerland. Sub- 
tilisin Carlsberg was the kind gift of Dr I. Svend- 
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sen, Carlsberg Laboratories, Copenhagen. Eglin-c 
has the same sequence as native eglin and consists 
of 70 amino acid residues (fig.1) [7]; IW, = 7990. 
Subtilisin Carlsberg consists of 274 residues [8]; 
A4, = 27240. Crystals of the complex were grown 
by the hanging-drop vapor-diffusion method from 
a solution of 0.7 M KH2P04 and H3P04, buffered 
to pH 5.6. The crystals have unit cell dimensions of 
a = 38.31(3) A, b = 41.41(4) A, c = 56.50(6) A, 
LY = 69.5(l)“, P = 83.7(2)“, and y = 75.3(l)“. The 
space group is Pl, with one molecule of the com- 
plex per unit cell. 
2.2. Structure determination and refinement 
X-ray intensity data were collected on an 
automated diffractometer and processed by stan- 
dard crystallographic techniques [9]. The method 
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Fig. 1. An a-carbon backbone drawing of eglin-c (thin 
lines) complexed to subtilisin Carlsberg (thick lines). 
Every 5th amino acid is labelled in the inhibitor, every 
10th in the enzyme. An I follows the sequence number 
of inhibitor residues to distinguish them from those of 
the enzyme. 
of molecular replacement was used to solve the 
phase problem for the structure of the eglin-c : sub- 
tilisin Carlsberg complex. The search model was 
the partially refined subtilisin novo molecule. The 
rotation search was performed with the fast rota- 
tion function [lo]. The eglin-c portion of the com- 
plex was recognized in the first map but the 
molecular structure was not completed until 
several cycles of refinement and model building 
were done. The first 7 residues in eglin-c are 
disordered. The MMS-X interactive graphics 
system [l l] with the macromolecular modelling 
system M3, developed by Broughton and co- 
workers [12], was used for map interpretation and 
model fitting. 
Refinement of the model was performed with 
the restrained-parameter least-squares refinement 
program of Hendrickson and Konnert [ 131, 
modified by Furey et al. [14], and locally by M. 
Fujinaga for the FPS164 attached processor. After 
19 cycles of refinement the R factor was reduced 
from 0.301 (6.0-2.8 A resolution) to 0.183 
(6.0-2.0 A resolution). The root-mean-square 
(rms) deviations from expected stereochemical 
parameters for cycle 19 are: 0.041 A for the 2492 
covalent bond distances; 0.062 A for the 3403 in- 
terbond angle distances; 0.018 A from the 432 
planar groups of the complex; and 3.2” for the 337 
peptide bond torsional angles. No water molecules 
have been included in the structural model. 
3. RESULTS AND DISCUSSION 
3.1. Structure of eglin-c 
The eglin-c molecule is a wedge-shaped isk with 
the reactive site loop at the narrow end of the 
wedge. This loop fits into the active site cleft of 
subtilisin (fig.1). CI-2 and the ovomucoid in- 
hibitors [9] are similarly shaped, although the 
polypeptide chain foldings of these 2 families are 
quite different. Eglin-c has 3 major secondary 
structural elements (fig.2): an a-helix of 3.6 turns, 
Thr 311-Tyr 431; a 4-stranded mixed parallel and 
antiparallel P-sheet, Lys 221-Phe 241, Asn 471- 
Leu 511, Arg 651-Tyr 701, and Val 751-Gly 831; 
and a wide loop crossover connection between 
parallel strands 3 and 4 of the sheet, Pro 561- 
Leu 611, containing the reactive site, Leu 59I- 
Asp 601. Reverse turns occur in the molecule at 
Phe 241-Val 271, Val 27I-Lys 301, Tyr 431-Ala 
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Fig.2. Amino acid sequences of eglin [7] and CI-2 [3], 
aligned according to 3-dimensional structure homology. 
Sequence numbering is that of CI-2. The reactive site 
bond is indicated by the arrow. The 22 identical residues 
are boxed. Residues before the vertical dashed lines are 
not seen in the electron density maps of the 2 
enzyme :inhibitor complexes. Secondary structural 
elements: LY, a-helix; ,L?, D-sheet; T, reverse turn. 
461, Pro 521-Thr 551, Arg 621-Arg 651, and 
Asn 71I-Thr 731. The a-helix packs against the 
characteristic urvature of the twisted &sheet and 
the interface between these elements is the 
hydrophobic core of eglin-c. 
A least-squares uperposition of the 62 struc- 
turally equivalent a-carbon atoms of eglin-c and 
CI-2 (program of W. Bennett) gives an rms devia- 
tion of 1.67 A between the 2 molecules. The largest 
deviations are at the beginning of the reactive site 
loop (residues 551-561), and near the end of the LY- 
helix (residues 411-421) (fig.3). Despite these dif- 
ferences, the mode of binding to their cognate en- 
zymes appears very similar for the 2 inhibitors. 
This may indicate small adjustments of enzyme 
and/or inhibitor conformation to achieve an ‘in- 
duced fit’. The conformation of the inhibitor reac- 
tive site loop of both eglin-C and CI-2 similar to 
that of the Kazal inhibitors [9], although the 
folding of the remainer of the polypeptide chain is 
unrelated for the 2 families. 
3.2. Structure of subtilisin Carlsberg 
There are 84 amino acid changes and one dele- 
tion between the sequences of subtilisin nova and 
subtilisin Carlsberg [5,8]. Most of the sequence 
changes occur on exterior loops of the molecule. A 
least-squares uperposition of the 274 structurally 
equivalent a-carbon atoms of the 2 subtilisins (pro- 
gram of W. Bennett) gives an rms deviation of 
0.53 A. This indicates that the 2 enzymes are ex- 
traordinarily similar. 
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